FAQ

Monoclonal Antibody Therapy

Known as: antibody therapy, monoclonal, monoclonal antibody therapies, MoAb 
The use of monoclonal antibodies in the treatment of any disease or disorder.

Topic mentions per year

Topic mentions per year

1980-2018
010020019802018

Related topics

Related topics

3 relations

Broader (1)

Immunotherapy
Monoclonal Antibodiesantibody therapy

Related mentions per year

Related mentions per year

1947-2018
19401960198020002020
Monoclonal Antibody Therapy
Monoclonal Antibodies
Immunotherapy
antibody therapy

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2013
Highly Cited
2013
Therapeutic Efficacy of Potent Neutralizing HIV-1-Specific Monoclonal Antibodies in SHIV-Infected Rhesus Monkeys
Human immunodeficiency virus type 1 (HIV-1)-specific monoclonal antibodies with extraordinary potency and breadth have recently… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
Highly Cited
2009
Highly Cited
2009
Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective French Research Axed on…
OBJECTIVE Tuberculosis (TB) is associated with anti-tumor necrosis factor (anti-TNF) monoclonal antibody (mAb) therapy, but… (More)
  • figure 1
  • figure 2
  • figure 3
  • table 1
  • table 2
Is this relevant?
Highly Cited
2000
Highly Cited
2000
Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment.
PURPOSE This phase II trial investigated the safety and efficacy of re-treatment with rituximab, a chimeric anti-CD20 monoclonal… (More)
Is this relevant?
Highly Cited
1998
Highly Cited
1998
Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.
PURPOSE The CD20 antigen is expressed on more than 90% of B-cell lymphomas. It is appealing for targeted therapy, because it does… (More)
Is this relevant?
Highly Cited
1997
Highly Cited
1997
IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma.
IDEC-C2B8 is a chimeric monoclonal antibody (MoAb) directed against the B-cell-specific antigen CD20 expressed on non-Hodgkin's… (More)
  • table 1
  • table 2
  • table 3
  • figure 1
Is this relevant?
Highly Cited
1995
Highly Cited
1995
Anti-C5 monoclonal antibody therapy prevents collagen-induced arthritis and ameliorates established disease.
Activated components of the complement system are potent mediators of inflammation that may play an important role in numerous… (More)
  • figure 1
  • figure 2
  • table 1
  • figure 4
  • table 2
Is this relevant?
Highly Cited
1991
Highly Cited
1991
Murine anti-interleukin-6 monoclonal antibody therapy for a patient with plasma cell leukemia.
A patient with primary plasma cell leukemia resistant to chemotherapy was treated for 2 months with daily intravenous injections… (More)
  • table 1
  • figure 1
  • figure 2
Is this relevant?
Highly Cited
1987
Highly Cited
1987
Ganglioside GD2 specific monoclonal antibody 3F8: a phase I study in patients with neuroblastoma and malignant melanoma.
The murine IgG3 monoclonal antibody (MoAb) 3F8, specific for the ganglioside GD2, activates human complement, is active in… (More)
Is this relevant?
Highly Cited
1985
Highly Cited
1985
Human anti-murine immunoglobulin responses in patients receiving monoclonal antibody therapy.
Human anti-murine immunoglobulin responses were assessed in serum from three groups of patients receiving murine monoclonal… (More)
  • table 1
Is this relevant?
Highly Cited
1984
Highly Cited
1984
Growth inhibition of human tumor cells in athymic mice by anti-epidermal growth factor receptor monoclonal antibodies.
Monoclonal antibodies (MoAbs) were raised against epidermal growth factor (EGF) receptors on a human epidermoid carcinoma cell… (More)
  • table 3
Is this relevant?